Navigation Links
Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
Date:3/23/2009

SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC) 58th Annual Scientific Session in Orlando, Fla.

John R. Teerlink, M.D., professor of medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center will present the results from the multicenter, international Pre-RELAX-AHF study as part of an ACC special session entitled "Late-Breaking Clinical Trials I: Congestive Heart Failure."

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.

About Corthera

Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com.

    Contact:      Andreas Marathovouniotis or David Schull
                  Russo Partners
                  212.845.4235
                  andreas.marathis@russopartnersllc.com
              
'/>"/>
SOURCE Corthera
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Alcoa (NYSE: AA ) today announced a ... CDXS ) and CO2 Solution Inc. (TSX-V: CST), focused ... neutralizing the material to create a commercially viable product. ... world,s leading aluminum producer and will be funded by Alcoa ...
... a new market research report is available in its catalogue: ... http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html Global ... The Freedonia Group projects world demand for in vitro diagnostic ... in 2014. Based on the advanced nature of medical delivery ...
Cached Medicine Technology:Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 2Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 3Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 4Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 5Reportlinker Adds World In Vitro Diagnostics Market 2Reportlinker Adds World In Vitro Diagnostics Market 3Reportlinker Adds World In Vitro Diagnostics Market 4Reportlinker Adds World In Vitro Diagnostics Market 5Reportlinker Adds World In Vitro Diagnostics Market 6Reportlinker Adds World In Vitro Diagnostics Market 7Reportlinker Adds World In Vitro Diagnostics Market 8Reportlinker Adds World In Vitro Diagnostics Market 9
(Date:8/28/2015)... ... August 28, 2015 , ... ... Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in his ... begin with the employer and employees getting together for meaningful group meetings. "This ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for those seeking to go deep sea diving. The act of recreational ... decompression sickness; for these reasons, it is vital that all recreational and professional ...
(Date:8/28/2015)... ... August 28, 2015 , ... Popular review ... millionaire dating sites . According to the listings, MillionaireMatch.com bags ... this category. , A spokesperson of Top5MillionaireDatingSites.com said, “This website has ...
(Date:8/28/2015)... ... ... Inc. magazine today ranked PREVENT Life Safety No. 3660 on its ... The list was unveiled online at Inc.com and is the most competitive crop in ... ranks higher on the list than any other company in their industry. , PREVENT ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... generic drugs will get them into consumers, hands quicker, but ... marketing researcher has found. A mathematical model created by ... the chances of getting there first and commanding the best ... Ching is an associate professor of marketing at the University ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, Feb. ... levels of exposure to a substance found in a commonly ... a mental developmental test at 3 years of age than ... at all, new research says. Megan Horton, a postdoctoral ...
... , PHILADELPHIA - So-called barrier sites -- the skin, ... allergens, pollutants, viruses, bacteria, and parasites. Understanding how the ... for understanding such inflammatory diseases as asthma, psoriasis, IBD, ... body,s barriers. David Artis, PhD, professor of ...
... , MONDAY, Feb. 7 (HealthDay News) -- The ... along with the economy, statistics released Monday suggest. ... performed in the country, up five percent from 2009, ... nearly 1.6 million cosmetic surgical procedures and 11.6 cosmetic ...
... PICK: Profiling malaria-causing parasites The majority of ... parasite Plasmodium falciparum . Most at risk are young ... led by Patrick Duffy, at the National Institutes of Health, ... falciparum parasites in such a way that they are ...
... gambling rates continue to rise, University of Missouri researchers ... as an effective and inexpensive way for people with ... Matthew Martens, associate professor of Educational, School and ... his team of researchers received a $172,500 grant ...
Cached Medicine News:Health News:Prenatal Exposure to Pesticides May Harm Kids' Development 2Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:JCI online early table of contents: Feb. 7, 2011 2Health News:JCI online early table of contents: Feb. 7, 2011 3Health News:JCI online early table of contents: Feb. 7, 2011 4Health News:JCI online early table of contents: Feb. 7, 2011 5Health News:JCI online early table of contents: Feb. 7, 2011 6Health News:JCI online early table of contents: Feb. 7, 2011 7Health News:Simple feedback could be effective therapy for addictive behaviors 2
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Currettes...
Townsend is a endocervical stainless-steel curette with round tapered tip....
Medicine Products: